Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis - PubMed
4 hours ago
- #Clinical Trial
- #Long-term Follow-up
- #Follicular Lymphoma
- The 10-year RELEVANCE trial compared rituximab plus lenalidomide (R2) to rituximab-based immunochemotherapy (R-Chemo) in previously untreated advanced follicular lymphoma.
- Median progression-free survival (PFS) was similar between groups (110.6 months for R2 vs. 102.8 months for R-Chemo), with 10-year PFS rates around 46%.
- Overall survival rates at 10 years were high and comparable (82.4% for R2 vs. 81.1% for R-Chemo), and median OS was not reached in either arm.
- Time to next lymphoma treatment (TTNLT) rates at 10 years were 62.2% for R2 and 66.3% for R-Chemo, with medians not reached.
- Early progression (POD24) indicated poorer prognosis but did not differ between treatment groups.
- Second primary malignancies occurred at a rate of 2.11 cases per 100 patient-years, and only 9 transformations occurred after 24 months.
- R2 was confirmed as a chemotherapy-free alternative to immunochemotherapy for this patient population.